Company intelligence / Profile preview

Eysz

Bay Area/San Francisco Bay Area, California, United Stateseyszlab.com ↗

Ownership: Private
Development stage: Commercial

Overview

Eysz has completed market validation studies and initiated clinical studies with academic partners. The company’s AI-driven software analyzes eye movements to objectively measure symptoms in epilepsy and other neurological disorders. Validation and regulatory milestones are ongoing; FDA submission was targeted for late 2023. No commercial or pivotal trial results reported yet.

Therapeutic areas: Neurology
Modalities: DeviceSoftware (AI-based clinical decision support)Digital biomarker platform
Industry: Digital Health Medical Devices

Partnerships

UCB Pharma (investor/partner)Plug and Play Tech Center (investor/accelerator)Academic partnerships with UC San DiegoUCSFCHOC Children’s HospitalWake Forest University School of MedicineTexas Child Neurology

Beyond the preview

Go deeper on Eysz.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eysz.

Explore the full profile